MedTrace Logo

Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy

NCT01810237 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-01-31

No results posted yet for this study

Summary

Research Questions:

1. Does using dabigatran bridging result in consistent therapeutic anticoagulation? What percentage of patients will become subtherapeutic on warfarin once dabigatran is stopped?
2. What is the incidence of bleeding events with the use of dabigatran overlapped with warfarin for bridging?
3. What is the cost benefit of using dabigatran instead of dalteparin for bridging anticoagulation?

Conditions

  • Venous Thromboses

Interventions

DRUG

Dabigatran.

Dabigatran will be used instead of LMWH for anticoagulation bridging.

Sponsors & Collaborators

  • Nova Scotia Health Authority

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-07-31
Completion
2013-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01810237 on ClinicalTrials.gov